Clinical Trial Detail

NCT ID NCT02368691
Title Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors GTx
Indications

triple-receptor negative breast cancer

Therapies

enobosarm

Age Groups: senior adult

No variant requirements are available.